The European Commission's Health Emergency Preparedness and Response Authority (HERA) has handed over 10,000 doses of Jynneos monkeypox vaccine to Ukraine.
Ukraine received the vaccine as humanitarian aid within the framework of EU4Health – the EU health care program, which Ukraine joined in July 2022. The vaccine will be distributed and transported by the Ministry of Health to the regions according to the collected needs. Vaccination of people belonging to risk groups will be carried out free of charge.
Jynneos is a live attenuated smallpox and monkeypox vaccine developed by Bavarian Nordic. The vaccine is intended for people 18 years of age and older who are at high risk of contracting smallpox or monkeypox. A full course of vaccination against monkeypox consists of two doses with an interval of 28 days. People who have previously received the smallpox vaccine need to be vaccinated only if more than 10 years have passed since the vaccination.
Vaccination against monkeypox is recommended for healthcare workers who are at risk of exposure to monkeypox and for people who are at high risk of infection.
Certificate:
Monkeypox is a smallpox-like disease caused by viruses of the poxvirus family. Its symptoms are very similar to natural smallpox. It is transmitted through any close physical contact with a rash on the body of an infected person, through coughing or sneezing, touching clothes, bedding, towels used by a monkey pox patient. It is also possible to get infected from infected animals in West and Central Africa.
In most cases, monkey pox is much milder than natural pox. However, sometimes it can still lead to fatalities.
Until 2022, monkeypox was recorded mainly in the countries of Central and West Africa, currently most new cases are recorded in South and North America, there are cases of the disease in Europe. Cases of monkeypox have also been recorded in Ukraine.
Comments